NodThera: Inhibiting the inflammasome for NASH

How NodThera is tackling NASH with NLRP3 inflammasome inhibitors

NodThera Ltd. is tackling both the inflammation and fibrosis that drive NASH by inhibiting the NLRP3 inflammasome, a target few companies have interrogated for the indication.

With a £28 million ($37 million) series A led by Sofinnova Partners and 5AM Ventures, NodThera plans to take its lead compound, NT-0167, through early Phase II testing.

The inflammasome is a cytosolic multiprotein complex that induces secretion of IL-1β

Read the full 640 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE